Abstract
The autistic spectrum disorders (ASD) form a set of multi-faceted disorders with significant genetic, epigenetic and environmental determinants. Oxidative and nitrosative stress (O&NS), immuno-inflammatory pathways, mitochondrial dysfunction and dysregulation of the tryptophan catabolite (TRYCATs) pathway play significant interactive roles in driving the early developmental etiology and course of ASD. O&NS interactions with immunoinflammatory pathways mediate their effects centrally via the regulation of astrocyte and microglia responses, including regional variations in TRYCATs produced. Here we review the nature of these interactions and propose an early developmental model whereby different ASD genetic susceptibilities interact with environmental and epigenetic processes, resulting in glia biasing the patterning of central interarea interactions. A role for decreased local melatonin and N-acetylserotonin production by immune and glia cells may be a significant treatment target.
Keywords: Autism, glia, immuno-inflammation, melatonin, nitrosative stress, oxidative stress, tryptophan.
Current Neuropharmacology
Title:Redox Regulation and the Autistic Spectrum: Role of Tryptophan Catabolites, Immuno-inflammation, Autoimmunity and the Amygdala
Volume: 12 Issue: 2
Author(s): George Anderson and Michael Maes
Affiliation:
Keywords: Autism, glia, immuno-inflammation, melatonin, nitrosative stress, oxidative stress, tryptophan.
Abstract: The autistic spectrum disorders (ASD) form a set of multi-faceted disorders with significant genetic, epigenetic and environmental determinants. Oxidative and nitrosative stress (O&NS), immuno-inflammatory pathways, mitochondrial dysfunction and dysregulation of the tryptophan catabolite (TRYCATs) pathway play significant interactive roles in driving the early developmental etiology and course of ASD. O&NS interactions with immunoinflammatory pathways mediate their effects centrally via the regulation of astrocyte and microglia responses, including regional variations in TRYCATs produced. Here we review the nature of these interactions and propose an early developmental model whereby different ASD genetic susceptibilities interact with environmental and epigenetic processes, resulting in glia biasing the patterning of central interarea interactions. A role for decreased local melatonin and N-acetylserotonin production by immune and glia cells may be a significant treatment target.
Export Options
About this article
Cite this article as:
Anderson George and Maes Michael, Redox Regulation and the Autistic Spectrum: Role of Tryptophan Catabolites, Immuno-inflammation, Autoimmunity and the Amygdala, Current Neuropharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/1570159X11666131120223757
DOI https://dx.doi.org/10.2174/1570159X11666131120223757 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Medical Management and Risk Reduction of the Cardiovascular Effects of Underwater Diving
Current Vascular Pharmacology The Neuropharmacological Preclinical Effects of <i>Nigella sativa</i>: A Review
Current Bioactive Compounds In Search of Novel AMPA Potentiators
Recent Patents on CNS Drug Discovery (Discontinued) Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Routine Collection of Patient-Reported Outcomes in an HIV Clinic Setting:The First 100 Patients
Current HIV Research Molecular Properties Prediction, Docking Studies, and Antimicrobial Screening of 1,3,4-Thiadiazole and s-Triazole Derivatives
Current Computer-Aided Drug Design Zebrafish Model in Drug Safety Assessment
Current Pharmaceutical Design Retraction Notice: Potential Application of Venom Proteins in Designing of Medicines for Treating Human Neurodegenerative Disorders
Protein & Peptide Letters 1,3,4-Thiadiazole: A Versatile Pharmacophore of Medicinal Significance
Medicinal Chemistry Modulation of GABAA Receptors in the Treatment of Epilepsy
Current Pharmaceutical Design Advances in the Treatment of Autism Spectrum Disorder: Current and Promising Strategies
Current Medicinal Chemistry N-Aryl-5-aminopyrazole: A Versatile Architecture in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Updates on the Synthetic Strategies and Structure-Activity Relationship of Anticonvulsant Benzothiazole and Benzimidazole Derivatives
Letters in Drug Design & Discovery Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials A Comprehensive Review on Recent Developments in the Field of Biological Applications of Potent Pyrazolines Derived from Chalcone Precursors
Letters in Drug Design & Discovery Synthesis and Anticonvulsant Activity Evaluation of 4-butyl-5-(4- alkoxyphenyl)-2H-1,2,4-triazole-3(4H)-ones
Letters in Drug Design & Discovery Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Glial Cells – The Key Elements of Alzheimer´s Disease
Current Alzheimer Research A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets Transcriptional Dys-regulation in Anxiety and Major Depression: 5-HT1A Gene Promoter Architecture as a Therapeutic Opportunity
Current Pharmaceutical Design